Valuation: Novartis

Market Cap 294B 254B 239B 217B 408B 28,139B 414B 2,799B 1,097B 14,073B 1,103B 1,079B 46,876B P/E 2026 *
21.9x
P/E 2027 * 18.7x
Enterprise Value 327B 282B 266B 241B 454B 31,311B 461B 3,115B 1,221B 15,660B 1,227B 1,200B 52,162B EV / Sales 2026 *
5.66x
EV / Sales 2027 * 5.25x
Free-Float
91.66%
Yield 2026 *
2.83%
Yield 2027 * 2.95%
Manager TitleAgeSince
Chief Executive Officer 50 01/02/2018
Director of Finance/CFO - 16/03/2026
Compliance Officer 58 14/04/2025
Director TitleAgeSince
Director/Board Member 67 01/01/2015
Director/Board Member 69 01/01/2016
Director/Board Member 61 01/01/2016
Change 5-day change 1-year change 3-year change Capi.($)
+78.36%0.00% - - 294B
+3.60%+0.88%+75.59%+124.32% 1,093B
+3.33%+4.35%+53.82%+57.17% 653B
+3.43%+3.53%+25.34%+72.45% 458B
+0.61%-0.74%+39.43%+42.67% 355B
+0.18%+1.11%+24.46%+39.53% 294B
+0.47%+1.20%+0.51%+10.95% 248B
+1.41%+2.65%+45.34%+62.43% 230B
-1.04%-1.94%-15.62%-53.43% 203B
+3.25%+5.65%+21.57%+89.04% 178B
Average +1.54%+1.20%+30.05%+49.46% 412.27B
Weighted average by Cap. +2.20%+1.45%+43.59%+68.76%

Financials

2026 *2027 *
Net sales 57.71B 49.84B 46.89B 42.62B 80.16B 5,529B 81.34B 550B 216B 2,765B 217B 212B 9,211B 61.25B 52.9B 49.78B 45.24B 85.09B 5,869B 86.34B 584B 229B 2,935B 230B 225B 9,777B
Net income 13.95B 12.05B 11.34B 10.3B 19.38B 1,337B 19.66B 133B 52.12B 669B 52.38B 51.24B 2,227B 15.5B 13.39B 12.6B 11.45B 21.53B 1,485B 21.85B 148B 57.91B 743B 58.2B 56.94B 2,474B
Net Debt 33.11B 28.6B 26.91B 24.46B 46B 3,173B 46.67B 316B 124B 1,587B 124B 122B 5,286B 27.82B 24.03B 22.61B 20.54B 38.64B 2,665B 39.21B 265B 104B 1,333B 104B 102B 4,440B
Logo Novartis
Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales break down by therapeutic area as follows: - oncology (30.9%); - immunology (18.9%); - cardiovascular, renal and metabolic diseases (16.4%); - neuroscience (11%). The remaining net sales (22.8%) are from contract manufacturing of pharmaceutical products. At the end of 2025, Novartis AG had over 31 production sites worldwide. Net sales are distributed geographically as follows: Switzerland (2.6%), Europe (28.1%), the United States (42.8%), Asia/Africa/Australasia (19.8%), Canada and Latin America (6.7%).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
AAA